A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy Subjects
This is a very early study, called a Phase 1 trial, looking into a new medicine named GTX-11. Its main purpose is to understand if this medicine is safe when given to healthy adult volunteers. We also want to see how well people tolerate different doses and how the medicine acts inside the body. This includes how much of it gets into the blood and how quickly it's removed. By doing this initial research, scientists can gather important information before potentially testing the medicine in people who actually have conditions like pulmonary fibrosis, a disease that causes scarring in the lungs. It's a crucial first step in developing new treatments.
At a glance
What is this study about?
Imagine you're building a new car. Before you put it on the road for everyone, you first test its basic parts to make sure they work safely. This study, known as a 'Phase 1' trial, is a bit like that. It's the very first time a new investigational medicine, called GTX-11, is being given to people.
The main goal here is not to treat an illness, but to carefully check how safe the medicine is. Researchers will give small, increasing amounts of GTX-11 to healthy volunteers to see if it causes any unwanted side effects and how well people tolerate it. They will also look at how the body handles the medicine – how it enters the bloodstream, how it's processed, and how it leaves the body.
This important first step helps scientists decide if GTX-11 has the potential to be studied further as a possible treatment for conditions like pulmonary fibrosis. Pulmonary fibrosis is a serious lung disease where the lung tissue becomes scarred and stiff, making it hard to breathe. By understanding the safety and basic behaviour of this new medicine now, researchers can make informed decisions about future studies that could one day benefit patients.
Key takeaways
- Tests a new medicine, GTX-11, for the very first time in people.
- Goal is to check safety and how the body handles the medicine.
- Involves healthy adult volunteers, aged 18 and over.
- Participants may receive the medicine or a placebo (dummy medicine).
- Involves clinic visits, possibly overnight stays, blood tests, and health checks.
- Participation helps scientists learn for future treatments, but no direct health benefit is expected for you.
Who may be eligible?
This study is looking for healthy adult volunteers, aged 18 years and older (there's no upper age limit). Both men and women can take part.
Because this is a very early study testing a new medicine for the first time, strict rules are in place to make sure every participant is as healthy as possible. This helps researchers clearly see how the new medicine affects the body without other health conditions getting in the way.
During the screening process, a doctor will carefully check your overall health through examinations, blood tests, and other checks to make sure this study is safe for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you considered generally healthy?
- Are you able to attend several clinic visits, including possible overnight stays?
- Are you comfortable with blood tests and other medical checks?
- Are you willing to potentially take either the study medicine or a placebo?
What does participation involve?
If you decide to take part, you'll first have a screening visit to check your eligibility. If you qualify, you will then be assigned to receive either the study medicine (GTX-11) or a placebo (a dummy medicine with no active ingredient) at random. Neither you nor the study team will know which you are receiving – this is called 'double-blind'.
You will have several scheduled visits to the clinic, which will involve staying overnight for some periods. During these visits, the study team will give you the medicine, monitor you closely for any side effects, and take blood and urine samples to see how the medicine is working in your body. There will also be physical examinations and other tests to keep track of your health.
The study involves receiving either single doses or multiple doses over a period, depending on which group you are in. The total duration of your participation, including all visits and follow-up, will be explained in detail before you agree to join.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is a 'Phase 1' study?
It's the first time a new medicine is tested in people, usually healthy volunteers. The main goal is to check for safety and how the body handles it.
What is 'pulmonary fibrosis'?
It's a serious lung disease where the lungs become scarred and stiff, making it hard to breathe.
What does 'randomized' and 'double-blind' mean?
Randomized means you're put into a group by chance. Double-blind means neither you nor the doctors know if you're getting the active medicine or a dummy one (placebo).
Will I get paid for taking part?
Many Phase 1 studies offer some payment for your time, travel, and inconvenience. This will be fully explained to you before you agree to join.
Can I leave the study once I've started?
Yes, you can leave the study at any time, for any reason, without it affecting your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.